Statin-induced cholestatic hepatitis: confirmed on rechallenge.
作者信息
Kerzner Sam, Irabagon Nenita, Berkelhammer Charles
机构信息
Department of Medicine, University of Illinois, Oak Lawn, Illinois.
出版信息
Gastroenterol Hepatol (N Y). 2013 Sep;9(9):603-5.
Abstract
摘要
相似文献
1
Statin-induced cholestatic hepatitis: confirmed on rechallenge.他汀类药物引起的胆汁淤积性肝炎：再激发试验确诊。
Gastroenterol Hepatol (N Y). 2013 Sep;9(9):603-5.
2
Management Strategies for Statin-Associated Muscle Symptoms: How Useful Is Same-Statin Rechallenge?他汀类药物相关肌肉症状的管理策略：同他汀类药物再挑战有多有效？
Can J Cardiol. 2017 May;33(5):666-673. doi: 10.1016/j.cjca.2017.02.013. Epub 2017 Mar 2.
3
Trimethoprim-sulfamethoxazole-induced cholestatic hepatitis. Inadvertent rechallenge.
Arch Intern Med. 1984 Aug;144(8):1691-2. doi: 10.1001/archinte.144.8.1691.
4
Voriconazole-Induced Hepatitis via Simvastatin- and Lansoprazole-Mediated Drug Interactions: A Case Report and Review of the Literature.伏立康唑通过辛伐他汀和兰索拉唑介导的药物相互作用导致肝炎：一例病例报告及文献综述
Drug Metab Dispos. 2016 Jan;44(1):124-6. doi: 10.1124/dmd.115.066878. Epub 2015 Oct 26.
5
Acute severe hepatitis with alemtuzumab and rechallenge after a year.使用阿仑单抗后出现的急性重症肝炎及一年后的再次激发试验
J Clin Neurosci. 2019 Feb;60:158-160. doi: 10.1016/j.jocn.2018.10.055. Epub 2018 Oct 19.
6
Statin-induced liver injury in an area endemic for hepatitis B virus infection: risk factors and outcome analysis.乙型肝炎病毒感染流行地区他汀类药物所致肝损伤：危险因素及转归分析
Br J Clin Pharmacol. 2016 Sep;82(3):823-30. doi: 10.1111/bcp.13009. Epub 2016 Jun 17.
7
[Hepatic tolerance of atypical antipsychotic drugs].[非典型抗精神病药物的肝脏耐受性]
Encephale. 2002 Nov-Dec;28(6 Pt 1):542-51.
8
Carbimazole-induced acute cholestatic hepatitis.卡比马唑诱发的急性胆汁淤积性肝炎。
J Clin Gastroenterol. 1989 Feb;11(1):95-7. doi: 10.1097/00004836-198902000-00025.
9
Cloxacillin-induced cholestatic jaundice.
Am J Gastroenterol. 1986 Nov;81(11):1082-3.
10
Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge.他汀类药物相关性肌病：脂质门诊重新使用他汀类药物的耐受性经验
Cardiovasc Ther. 2012 Oct;30(5):e212-8. doi: 10.1111/j.1755-5922.2011.00267.x. Epub 2011 Apr 1.
引用本文的文献
1
Statin-induced Liver Injury Patterns: A Clinical Review.他汀类药物所致肝损伤模式：一项临床综述
J Clin Transl Hepatol. 2022 Jun 28;10(3):543-552. doi: 10.14218/JCTH.2021.00271. Epub 2022 Jan 10.
2
Atorvastatin alters the expression of genes related to bile acid metabolism and circadian clock in livers of mice.阿托伐他汀可改变小鼠肝脏中与胆汁酸代谢和生物钟相关的基因表达。
PeerJ. 2017 May 18;5:e3348. doi: 10.7717/peerj.3348. eCollection 2017.
3
Statins and liver injury.他汀类药物与肝损伤。
Gastroenterol Hepatol (N Y). 2013 Sep;9(9):605-6.
本文引用的文献
1
The adaptive response (drug tolerance) helps to prevent drug-induced liver injury.适应性反应（药物耐受性）有助于预防药物性肝损伤。
Gastroenterol Hepatol (N Y). 2012 May;8(5):333-6.
2
Statin treatment in patients with elevated liver enzymes: pitch to proceed.
J Clin Lipidol. 2012 Jul-Aug;6(4):310-1. doi: 10.1016/j.jacl.2012.05.001. Epub 2012 May 22.
3
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.非酒精性脂肪性肝病的诊断与管理：美国胃肠病学会、美国肝病研究协会和美国胃肠病学院实践指南
Gastroenterology. 2012 Jun;142(7):1592-609. doi: 10.1053/j.gastro.2012.04.001. Epub 2012 May 15.
4
3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy.3-羟基-3-甲基戊二酰辅酶 A 还原酶抑制剂在慢性肝病中的应用：一个治疗争议。
J Clin Lipidol. 2011 Nov-Dec;5(6):450-9. doi: 10.1016/j.jacl.2011.06.013. Epub 2011 Jun 28.
5
Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing.他汀类药物相关的肝毒性：上市后报告的特异质性肝损伤。
J Hepatol. 2012 Feb;56(2):374-80. doi: 10.1016/j.jhep.2011.07.023. Epub 2011 Sep 1.
6
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.在希腊阿托伐他汀和冠心病评估（GREACE）研究中，对于有冠心病和肝功能异常的患者，长期他汀类药物治疗对心血管事件的安全性和有效性：一项事后分析。
Lancet. 2010 Dec 4;376(9756):1916-22. doi: 10.1016/S0140-6736(10)61272-X. Epub 2010 Nov 23.
7
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.非酒精性脂肪性肝病患者的心血管疾病风险
N Engl J Med. 2010 Sep 30;363(14):1341-50. doi: 10.1056/NEJMra0912063.
8
Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians.对肝毒性的担忧导致初级保健医生对他汀类药物的使用不足。
Am J Med Sci. 2010 Aug;340(2):89-93. doi: 10.1097/MAJ.0b013e3181e15da8.
9
Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma.他汀类药物在存在肝转氨酶水平升高的血脂异常治疗中的应用：一个治疗困境。
Mayo Clin Proc. 2010 Apr;85(4):349-56. doi: 10.4065/mcp.2009.0365.
10
Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study.一项基于人群的队列研究中疑似非酒精性脂肪性肝病与死亡风险
Am J Gastroenterol. 2008 Sep;103(9):2263-71. doi: 10.1111/j.1572-0241.2008.02034.x. Epub 2008 Aug 5.
Zotero 插件